GP方案与NP方案治疗非小细胞肺癌疗效及药物经济学评价

  目的 比较吉西他滨加顺铂（GP方案）与长春瑞滨加顺铂（NP方案）两种联合方案治疗晚期非小细胞肺癌（NSCLC）的疗效、毒副反应及药物经济学评价。方法 用GP方案治疗晚期NSCLC 39例（GP组）与NP方案治疗晚期NSCLC 37例（NP组），统计分析临床资料。结果 GP组有效率48.7 %，NP组有效率45.9 %，两组疗效差异无统计学意义（P＞0.05），毒副反应主要为恶心呕吐、骨髓抑制。NP组的静脉炎较GP组多发，GP组血小板减少及皮疹发生率高于NP组，GP组的疾病进展时间较NP组延长（P＜0.05）。2疗程平均药物费用GP组￥（23 664±384.7）元，NP组￥（8519.94±369.1）元，有效率与所需费用之比GP组￥（485.02±34.65）元，NP组￥（185.62±23.77）元，中位生存期与所需费用之比GP组￥（2211.59±59.15）元，NP组￥（946.66±43.3）元，1年生存率与所需费用之比GP组￥（608.33±14.35）元，NP组￥（243.43±21.57）元。药物费用NP组明显低于GP组，费用疗效比NP组优于GP组（P＜0.05）。结论 两种方案均为治疗晚期NSCLC的一线方案，在治疗晚期NSCLC时可选用。

Comparative study of gemcitabine and cisplatin versus navelbine and cisplatin in the treatment of advanced non-small-cell lung cancer

Objective To compare the efficacy and toxicity of two new platinum-based chemothera－peutic regimens for advanced non-small-cell lung cancer (NSCLC), and to evaluate the two chemotherapeutic regimens by pharmacocconomic analysis. Methods The clinical data of 76 cases with advanced NSCLC treated with (1) gemcitabine plus cisplatin (GP group, 39cases), (2) navelbine plus cisplatin (NP group, 37cas－es) and were analysed. Results The response rate was 48.7 % in patients treated with GP, 46.9 % in those treated with NP respectively (P > 0.05). The major toxic reactions in the two groups was tolerable myelo-sup－pression. The average cost of one patient for two therapeutic cycles was ￥(23664±384.7) and ￥(8519.94±369.1) respectively. Escalation of 1 % of response rate costed ￥(485.02±34.65) and ￥(185.62±23.77) respectively. Prolongation of 1 month of median survival duration costed ￥(2211.59±59.1) and ￥(946.66±43.3) respectively.TTP in group GP is longer than that in group NP(P<0.05). Conclusion GP and NP are effective and safe chemotherapeutic protocols for the treatment of advanced NSCLC patients. The expenditure of NP is much cheaper than GP. They could be considered as a selective treatment regimen.